Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 8/20 | 0.46 |
| ▸ | ACE | P12821 | 6/20 | 0.46 |
| ▸ | CPA1 | P15085 | 5/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 5/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP7 | P09237 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP12 | P39900 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4174128 | 0.85 | CYP3A4 (0.41) | — | |
| SCHEMBL4175252 | 0.78 | ABCC3 (0.55) | MMEACECPA1ACE2MMP2 | |
| SCHEMBL12864507 | 0.71 | MME (0.69) | MMEACECPA1ACE2MMP2 | |
| SCHEMBL8510053 | 0.71 | MME (0.69) | MMEACECPA1ACE2MMP2 | |
| SCHEMBL8510050 | 0.71 | MME (0.69) | MMEACECPA1ACE2MMP2 | |
| SCHEMBL13915883 | 0.71 | ABCC3 (0.54) | MMP2MMP7 | |
| SCHEMBL31390164 | 0.70 | MME (0.63) | MMEACECPA1ACE2MMP2 | |
| SCHEMBL31390141 | 0.70 | MME (0.63) | MMEACECPA1ACE2MMP2 | |
| SCHEMBL15222315 | 0.70 | MME (0.67) | MMEACECPA1ACE2MMP2 | |
| SCHEMBL13907784 | 0.70 | ABCC3 (0.53) | MMEACECPA1ACE2MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090068719-A1 | IMMUNOASSAYS, HAPTENS, IMMUNOGENS AND ANTIBODIES FOR ANTI-HIV THERAPEUTICS | VALDEZ JOHNNY | 2009-03-12 | — | — | US | disclosed |
| US-20050244816-A1 | Immunoassays, haptens, immunogens and antibodies for anti-HIV therapeutics | ARK DIAGNOSTICS, INC. (US) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090068719-A1 | IMMUNOASSAYS, HAPTENS, IMMUNOGENS AND ANTIBODIES FOR ANTI-HIV THERAPEUTICS | CD4, MPI, ME1 | MME 26/4885ACE 7/4885CPA1 754/4885 |
| US-20050244816-A1 | Immunoassays, haptens, immunogens and antibodies for anti-HIV therapeutics | CD4, MPI, ME1 | MME 26/4885ACE 7/4885CPA1 754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.